## Management of Inadequately Controlled Asthma **Key Point:** A patient requiring rescue bronchodilators >2 days per week (or >2 nights per month) meets criteria for persistent asthma and requires controller therapy, not escalation of rescue medication alone. ### Asthma Control Classification & Step Therapy | Control Level | Daytime Symptoms | Nighttime Awakenings | Recommended Controller | |---|---|---|---| | Intermittent | ≤2 days/week | ≤2 nights/month | PRN SABA only | | Mild persistent | >2 days/week, <1/day | 3–4 nights/month | ICS monotherapy | | Moderate persistent | Daily | 1–3 nights/week | **ICS + LABA** | | Severe persistent | Throughout day | ≥4 nights/week | High-dose ICS + LABA ± LAMA | **Clinical Pearl:** This patient's FEV₁ of 65% predicted and frequent rescue use (4–5 times daily) indicate **moderate persistent asthma**, placing him at Step 3 of the Global Initiative for Asthma (GINA) stepwise approach. ### Why ICS + LABA is Optimal 1. **Synergistic effect:** LABAs enhance ICS responsiveness and reduce airway inflammation more effectively than either agent alone. 2. **Reduced exacerbation risk:** ICS + LABA combination reduces exacerbations by ~25% compared to ICS monotherapy. 3. **Guideline-aligned:** GINA, NAEPP, and Indian Asthma Management Guidelines all recommend ICS + LABA for Step 3 asthma. 4. **Safety:** LABA should NEVER be used as monotherapy in asthma (increased mortality risk); it must be paired with ICS. **High-Yield:** The "LABA rule" — LABAs in asthma MUST always be combined with an ICS. Never prescribe LABA monotherapy. **Mnemonic: STEP-UP asthma therapy** - **S**ABAs only → mild intermittent - **T**hink ICS for persistent disease - **E**scalate to ICS + LABA for moderate - **P**otent: add LAMA or LTRA if inadequate control [cite:GINA 2023 Guidelines; Harrison 21e Ch 297]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.